Transdermal iontophoretic delivery of triptorelin in vitro.

The feasibility of delivering triptorelin ([D-Trp6]LHRH) by transdermal iontophoresis was evaluated in vitro. Peptide electrotransport at different current densities and donor concentrations was measured across porcine ear skin. The concomitant delivery of an electroosmotic marker enabled calculation of the respective contributions of electromigration (EM) and electroosmosis (EO) to iontophoretic delivery. At a given concentration (3 mM), a threefold increase in current density produced a corresponding increase in the cumulative amount of peptide present in the receptor compartment. Conversely, doubling the concentration to 6 mM produced a twofold reduction in the amount of peptide delivered, partly due to a concentration-dependent inhibition of EO. EM was revealed to be the predominant transport mechanism, accounting for 80% of overall delivery. Finally, despite the inhibition of EO, the results indicate that application of an iontophoretic current of 0.8 mA over a relatively small contact area (4 cm2) would provide a delivery rate of 36 microg/h, largely sufficient for therapeutic requirements.

[1]  M. Heit,et al.  Transdermal lontophoretic Delivery of Luteinizing Hormone Releasing Hormone (LHRH): Effect of Repeated Administration , 1994, Pharmaceutical Research.

[2]  D. Jacqmin,et al.  Three-Month Sustained-Release Form of Triptorelin in Patients with Advanced Prostatic Adenocarcinoma: Results of an Open Pharmacodynamic and Pharmacokinetic Multicenter Study , 1998, Hormone Research in Paediatrics.

[3]  R. Schall,et al.  Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. , 2003, British journal of clinical pharmacology.

[4]  R. Guy,et al.  Iontophoresis of Nafarelin Across Human Skin in Vitro , 1996, Pharmaceutical Research.

[5]  Michael J. Pikal,et al.  The role of electroosmotic flow in transdermal iontophoresis , 1992 .

[6]  L. Miller,et al.  Transdermal iontophoresis of gonadotropin releasing hormone (LHRH) and two analogues. , 1990, Journal of pharmaceutical sciences.

[7]  R. Guy,et al.  Cutaneous Metabolism of Nitroglycerin in Vitro. II. Effects of Skin Condition and Penetration Enhancement , 1992, Pharmaceutical Research.

[8]  W. H. M. Craane-van Hinsberg,et al.  Iontophoresis of a Model Peptide Across Human Skin in Vitro: Effects of Iontophoresis Protocol, pH, and Ionic Strength on Peptide Flux and Skin Impedance , 1994, Pharmaceutical Research.

[9]  H. Hui,et al.  The Effects of Formulation Variables on Iontophoretic Transdermal Delivery of Leuprolide to Humans , 1993 .

[10]  Aarti Naik,et al.  Iontophoretic drug delivery. , 2004, Advanced drug delivery reviews.

[11]  Y. Kalia,et al.  Contributions of Electromigration and Electroosmosis to Iontophoretic Drug Delivery , 2001, Pharmaceutical Research.

[12]  W. Ting,et al.  Review of traditional and novel modalities that enhance the permeability of local therapeutics across the stratum corneum , 2004, International journal of dermatology.

[13]  T. Redelmeier,et al.  4 Prediction and Measurement of Percutaneous Absorption , 1996 .

[14]  S. Santoyo,et al.  Penetration enhancer effects on the in vitro percutaneous absorption of piroxicam through rat skin , 1995 .

[15]  R. Burnette,et al.  Comparison between the iontophoretic and passive transport of thyrotropin releasing hormone across excised nude mouse skin. , 1986, Journal of pharmaceutical sciences.

[16]  C. Flamigni,et al.  Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. , 1994, The Journal of clinical endocrinology and metabolism.

[17]  R. Guy,et al.  A New System for In Vitro Studies of Iontophoresis , 1988, Pharmaceutical Research.

[18]  R. Guy,et al.  In vitro and in vivo iontophoresis of a tripeptide across nude rat skin , 1992 .

[19]  R. Guy,et al.  Iontophoresis of nafarelin: Effects of current density and concentration on electrotransport in vitro , 1995 .

[20]  J. C. Keister,et al.  Application of electrodiffusion theory for a homogeneous membrane to iontophoretic transport through skin , 1989 .

[21]  M. Roberts,et al.  Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? , 2004, Current drug delivery.

[22]  Y. Kalia,et al.  Transdermal delivery of peptides by iontophoresis , 1996, Nature Biotechnology.

[23]  A. Schally.  Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆ , 1999, Peptides.

[24]  Y. Kalia,et al.  Transdermal Iontophoretic Delivery of Vapreotide Acetate AcrossPorcine Skin in Vitro , 2005, Pharmaceutical Research.

[25]  R. Guy,et al.  Characterization of Convective Solvent Flow During Iontophoresis , 1994, Pharmaceutical Research.

[26]  R. Guy,et al.  Iontophoretic delivery of nafarelin across the skin , 1995 .

[27]  W. Kreis,et al.  Transdermal versus subcutaneous leuprolide: A comparison of acute pharmacodynamic effect , 1990, Clinical pharmacology and therapeutics.